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Abstract Oral emtricitabine/tenofovir disoproxil fuma-
rate (FTC/TDF) has been evaluated as pre-exposure pro-
phylaxis (PrEP). We describe the accuracy of self-reported
adherence to FTC/TDF and pill counts when compared to
drug concentrations in the FEM-PrEP trial. Using drug
concentrations of plasma tenofovir (TFV) and intracellular
tenofovir diphosphate (TFVdp) among a random sub-sam-
ple of 150 participants assigned to FTC/TDF, we estimated
the positive predictive value (PPV) of four adherence
measures. We also assessed factors associated with
misreporting of adherence using multiple drug-concentra-
tion thresholds and explored pill use and misreporting using
semi-structured interviews (SSIs). Reporting use of C1 pill
in the previous 7 days had the highest PPV, while pill-count
data consistent with missing B1 day had the lowest PPV.
However, all four measures demonstrated poor PPV.
Reported use of oral contraceptives (OR 2.26; p = 0.014)
and weeks of time in the study (OR 1.02; p\ 0.001) were
significantly associated with misreporting adherence.
Although most SSI participants said they did not misreport
adherence, participant-dependent adherence measures were
clearly unreliable in the FEM-PrEP trial. Pharmacokinetic
monitoring remains the measure of choice until more reli-
able participant-dependent measures are developed.
Keywords PrEP  Adherence  Positive predictive value 
Self-report  Pill-count
Introduction
In the past decade, oral tenofovir disoproxil fumarate
(TDF) with or without emtricitabine (FTC) has been
evaluated in clinical trials as pre-exposure prophylaxis
(PrEP) for its safety and efficacy in preventing HIV
acquisition [1–7]. Several studies have demonstrated that
PrEP is efficacious and that higher adherence levels lead to
higher levels of effectiveness [2, 4, 5, 8]. In contrast, the
FEM-PrEP and Vaginal and Oral Interventions to Control
the Epidemic (VOICE) trials did not show any effect of
oral TDF, oral FTC/TDF, or vaginal TDF gel on HIV
acquisition in women. Despite excellent self-reported
adherence by participants, investigators from both trials
cited low actual adherence as the likely reason for the lack
of efficacy [3, 6].
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Methods for measuring adherence in clinical trials often
include participant self-report, electronic monitoring devi-
ces, pill counts, pharmacy refills, and drug concentrations
in biological samples. Each measure has its own strengths
and weaknesses [9]. Data from participant self-report (the
most common adherence measure) are subject to bias, as
their accuracy depends on the participants’ memory or
comfort in providing truthful responses. Biomarkers, such
as drug concentrations in plasma, can be costly to imple-
ment. Further, plasma concentrations may only provide
information about the last few days of drug dosing and may
be subject to ‘‘white-coat adherence’’ bias, whereby a
participant only takes the drug shortly before a study visit
to give the appearance of adhering. Other biological mea-
sures, such as intracellular levels in peripheral blood
mononuclear cells or red blood cells or measures of drug
concentrations in hair samples, may provide a more com-
prehensive understanding of longitudinal adherence.
FEM-PrEP was a phase III, randomized, double-blind,
placebo-controlled trial to assess the efficacy and safety of
once-daily FTC/TDF in reducing HIV acquisition among
women who were at higher risk of HIV infection [3]. Here,
we use drug concentration data on plasma tenofovir (TFV)
and intracellular tenofovir diphosphate (TFVdp) to assess
the accuracy of three self-report measures and one pill-
count measure of adherence from the FEM-PrEP clinical
trial. We also describe qualitative data on non-adherence,
the misreporting of adherence, and participants’ comfort
level in reporting occurrences of non-adherence.
Methods
Ethics Statement
All associated ethics and regulatory committees approved
the trial. All trial participants provided written informed
consent prior to their participation.
Study Overview
Details of the FEM-PrEP trial have been reported else-
where [3]. Briefly, a total of 2,120 participants were
enrolled at four African sites: Bondo, Kenya; Pretoria and
Bloemfontein, South Africa; and Arusha, Tanzania. Par-
ticipants received client-centered adherence counselling
every 4 weeks for up to 52 weeks [10]. Adherence coun-
selling was provided by trained counsellors; participants’
answers to the quantitative study-product adherence ques-
tionnaire were not reviewed by counselors prior to coun-
seling. Pharmacists provided limited pill-taking messages
when dispensing pill bottles.
Data Collection
Quantitative Participant Self-Report
Toward the beginning of every visit and prior to counseling
on adherence, local FEM-PrEP study interviewers admin-
istered a quantitative study-product adherence question-
naire at the study clinic; counselors did not administer the
questionnaire. During this face-to-face interview, partici-
pants were asked the number of days they took the study
pill in the past 7 days and how often (never, rarely/almost
never, sometimes, usually/almost usually, or always) they
took the study pill in the past 4 weeks. Various techniques
thought to improve the reliability of participants’ responses
were used, such as using a shorter time interval for
recalling the number of pills taken; using an estimation
question for longer time intervals; and letting participants
know at the beginning of the interview that study staff
members understand that some participants may adhere
and some may not, to make clear that perfect adherence is
not expected [9]. Interviewers were also trained to assure
participants that they would not be upset with reports of
non-adherence, to not express an opinion on the responses
received, and to provide no counseling in response to
reported non-adherence.
Pill Counts
Each participant was given a bottle containing 30 pills at
visits scheduled for every 28 days (-4/?2 days). Staff
members were allowed to re-dispense up to seven previ-
ously returned pills; thus, a participant would take home
between 30 and 37 pills. At all visits, information was
obtained on the number of pills returned and dispensed.
The difference between the number of pills received at the
previous visit and the number of pills returned represented
the number of pills assumed used by pill count. This
number was compared with the number of days that had
elapsed between the previous visit and the current visit.
Plasma and Intracellular Drug Concentrations
Among a random sub-cohort of 150 participants assigned
to FTC/TDF (50 participants from each site where HIV
infections occurred: Bondo, Bloemfontein, and Pretoria),
we assessed stored plasma and upper layer of packed cells
(ULPCs) for TFV and FTC, and TFVdp and FTC-tri-
phosphate (FTCtp) drug concentrations, respectively, at
each follow-up visit. Details of the laboratory methods are
described elsewhere [11]. Briefly, analytes were measured
in plasma or ULPCs using protein precipitation followed
by liquid chromatography with tandem mass spectrometry.
All calibrators and quality control samples were within
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15 % of the nominal value for both within-day and
between-day runs.
Qualitative Interviews
We conducted SSIs with three groups of trial participants
to explore study pill use, misreporting of self-reported
adherence, and comfort level in reporting non-adherence.
The first group consisted of participants who seroconverted
at the Bondo and Pretoria sites and who returned for their
study visits. These interviews were conducted at weeks 1,
4, and 8 post-HIV diagnosis; questions on adherence were
asked at weeks 1 and 4. The second group consisted of
HIV-negative participants who were interviewed during the
trial (referred to as the ‘‘HIV-negative group’’). These
interviews were conducted every 3–4 months among a 5 %
random sample at the Bondo and Pretoria sites. We
explored different adherence-related topics during these
interviews using a standard set of questions. The adherence
topics varied at different time points, according to our
ongoing assessments of what information would be most
useful to inform trial implementation at the time. The
questions, however, remained the same whenever the topic
was explored in an interview. The third group was a ran-
dom sample of HIV-negative trial participants who com-
pleted at least one remaining study visit after the decision
was made to halt the study early because of lack of
effectiveness. These exit interviews were conducted at the
Bondo, Pretoria, and Bloemfontein sites. Each group
included participants who were randomized to receive
FTC/TDF or placebo.
All SSIs were conducted at the study clinic by local
members of the FEM-PrEP study staff. Interviewers were
different staff members from those who conducted the
quantitative study-product adherence questionnaire, and
they were not involved in any clinical or adherence-related
activities. Participants in all three groups were asked to
describe the context of any days in which they were unable
to take the study pill. Participants were also asked if they
ever misreported adherence to the study staff and, if so, the
reasons why; participants in the HIV-negative group were
asked these questions only at specific time points. During
the second year of trial implementation, we also asked
participants in the HIV-negative group to describe their
comfort level in reporting instances of non-adherence to
study staff members. The purpose of these questions was to
identify situations in which participants were unable to take
the study pills regularly, possible patterns of adherence,
and reasons for misreporting pill use in order to enhance
adherence counseling and reporting; our goal was not to
triangulate the qualitative and quantitative adherence data
because the SSIs did not focus on a specific time point.
Interviews were audiotaped when participants gave
permission. Expanded notes were taken for participants
who declined to be audiotaped.
Adherence Measures and Analysis Methods
We assessed the accuracy of four self-report and pill-count
adherence measures by estimating their PPV—the per-
centage of study visits where the adherence level indicated
by the measure was supported by drug-concentration data.
If the applicable drug concentration threshold was not
achieved, then we considered the participant to have mis-
reported her adherence (i.e., the probability of misreport for
a particular measure equals 1 minus the PPV of the mea-
sure). Appropriate drug thresholds for each measure were
selected based on TFV/FTC pharmacokinetic data in
plasma [11, 12] and previously determined TFVdp and
FTCtp concentrations in the ULPC matrix under steady-
state and single-dose conditions [12]. We used plasma TFV
concentrations (with a half-life of approximately 9 h) to
assess the accuracy of self-reported pill use in the 7 days
prior to specimen collection, and a composite measure of
TFV in plasma and TFVdp in ULPCs (with a half-life of
[72 h) to assess the accuracy of self-report and pill-count
data over 4 week intervals. The four adherence measures
were as follows.
Measure #1
Participant self-reports of taking pills on at least 6 of the
7 days prior to specimen collection, which would be con-
sistent with very high or perfect adherence in the previous
week. For this adherence level, a participant would have to
have taken a pill in the 24–48 h prior to the clinic visit, in
which case the TFV plasma level would be C10 ng/mL.
Measure #2
We were also interested in knowing whether participants
might report ‘‘any’’ pill taking more accurately than ‘‘high’’
or ‘‘perfect’’ adherence. Hence, in the second measure, we
assessed participant self-reports of taking at least one pill in
the 7 days prior to specimen collection. In this case, a
participant’s TFV level in plasma is expected to be
C0.25 ng/mL.
Measure #3
The third measure consisted of pill counts consistent with
the participant missing no more than 1 day of pill use
during the entire 4 week visit interval—which would cor-
respond to near-perfect adherence. For this adherence
level, the plasma TFV concentration is expected to be
C10 ng/mL and the concentration of TFVdp in ULPCs is
AIDS Behav (2015) 19:743–751 745
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expected to be C100,000 fmoles/mL. If the plasma TFV
concentration was \10 ng/mL, then the participant was
unlikely to have taken a pill in the previous 2 days. If her
TFVdp concentration was\100,000 fmoles/mL, then she
was unlikely to have taken pills consistently in the first few
weeks of the study interval.
Measure #4
The last measure consisted of participant self-reports that
they ‘‘usually’’ or ‘‘always’’ took the pills in the previous
4 weeks. For purposes of this analysis, we interpreted
‘‘usually or always’’ to mean taking at least five pills per
week. As for measure #3, a participant’s plasma TFV
concentration is expected to be C10 ng/mL and her con-
centration of TFVdp in ULPCs is expected to be C100,000
fmoles/mL if she usually or always took the pills.
The PPV of each measure was summarized overall and
by week of follow-up, after excluding: (1) intervals when
participants did not have sufficient product to cover the
visit interval (participants were not asked to report their
adherence if they missed their previously scheduled supply
visit and therefore could not have adhered as per protocol);
and (2) intervals that were\10 days (in which case TFVdp
concentrations might not reflect adherence during the
interval due to the long half-life of the metabolized drug).
We used logistic regression to assess associations
between misreporting adherence and three sets of factors:
those assessed at baseline, those assessed repeatedly during
trial participation, and those assessed when participants
exited the study. Generalized estimating equation methods
with robust variance estimation were used to account for
repeated measures on participants. Bivariate analyses were
conducted first, followed by a multivariate analysis that
initially included all bivariate factors with p\ 0.10, and
then backwards elimination to obtain a final model with
factors significant at the 0.05 level.
We evaluated baseline factors of site, age, education,
marital status, parity, use of highly effective contraception
at screening [oral contraceptives (OCs), intrauterine devi-
ces, implants, injectable contraceptives, or female sterili-
zation], use of OCs at enrollment, and having a sexually
transmitted infection (gonorrhea, chlamydia, syphilis, or
trichomoniasis). We also assessed time-dependent factors:
types of partners in the previous 4 weeks (primary partner
only versus more than one sexual partner); having sex
without a condom; having reported a gastrointestinal event
(nausea, vomiting, or diarrhea) any time prior to the visit;
and HIV risk perception (dichotomized as none versus
small, moderate or high chance due to the low frequency of
responses in each of the small, moderate and high cate-
gories). Factors we assessed from the participants’ last
adherence questionnaire included beliefs about their
randomly assigned treatment arm (placebo, FTC/TDF, or
‘‘don’t know’’) and how much participants liked taking the
daily pill. We made an a priori decision to use measure #1
(reports of using pills in 6 of the previous 7 days) for the
primary analysis of factors associated with the misreport of
adherence, but similar models were used to conduct sen-
sitivity analyses based on each remaining measure.
Applied thematic analysis was used to analyze the qual-
itative data [13]. Structural codes related to non-adherence,
reporting missed pills, and comfort level in reporting
adherence were applied to the interview text by two analysts
using NVivo 9 [14]. The analysts independently coded the
same samples of randomly selected transcripts, reviewed
codes, resolved differences, modified the codebook, and re-
coded as needed to ensure inter-coder reliability. Coding
reports were reviewed to identify themes, which were sub-
sequently confirmed by three analysts. Summary reports
were written to describe themes and to list frequencies and
illustrative quotes. For the interviews with participants who
seroconverted, we included data only from participants
whose clinical data contributed to the primary analysis of the
trial.
Results
The random sub-cohort of 150 participants assigned to FTC/
TDF were scheduled to make 1,364 visits prior to study
closure, out of which 1,172 (86 %) contributed to analyses
based on TFV concentrations alone (missed study visits and
protocol-defined product withdrawals accounted for nearly
all excluded data). A further 11 visits had insufficient
specimens for ULPC assessment, leaving 1,161 records for
analyses based on both TFV and TFVdp concentrations.
Pill Counts and Self-Reported Adherence
The pill-count data indicated that the participants missed
no more than 1 day of pill-taking during 82 % of eligible
study intervals. Participants reported taking pills on at least
1 of the previous 7 days at nearly all visits (99.6 %) and on
at least 6 of the previous 7 days at 94.7 % of visits. They
also reported usually or always taking pills in the previous
4 weeks at 99.1 % of visit intervals.
The PPVs of each measure are summarized in Table 1
for all visits combined, with PPV plotted over time in
Fig. 1. Measure #2 (reports of using at least one pill in the
previous 7 days) had the highest PPV, followed by Mea-
sure #1 (reports of using pills on at least 6 of the previous
7 days), Measure #4 (reports of usually or always taking
pills) and Measure #3 (pill-count data consistent with
missing no more than 1 day during the interval). Each of
the four measures demonstrated a poor PPV at week 4
746 AIDS Behav (2015) 19:743–751
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(27–56 %), which generally decreased over time (23–30 %
by week 52).
Factors Associated with Misreporting Adherence
In bivariate analyses, time in the study (OR 1.02 per week
of follow-up; p = 0.002) and choice of OCs to fulfill the
study’s requirement for the use of a contraceptive method
at enrollment (OR 2.13; p = 0.021) were each associated
with increased odds of misreporting adherence by Measure
#1 (Table 2). Having previously been pregnant (OR 0.57;
p = 0.084) and considering oneself to be at some risk of
HIV (OR 0.62; p = 0.057) were not significant but met our
pre-specified criteria for possible inclusion in an adjusted,
multivariate model. In the final model, only OC use at
enrollment (OR 2.26; p = 0.014) and time in the study
(OR 1.02 per week of follow-up; p\ 0.001) remained
significant. These two factors were also significantly
associated with the misreporting of adherence in sensitivity
analyses using each of the other self-reported measures and
the pill-count measure. However, considering oneself to be
at risk of HIV (p = 0.041) and not liking daily pill taking
(p = 0.026) were also associated with less misreporting for
Measure #2, and study site was associated with misrep-
orting for Measure #4 (p = 0.047, with participants from
Bloemfontein less likely to misreport; results not shown).
Semi-Structured Interviews
Fifty-six women who seroconverted were included in the
initial sample. Two of these participants were removed; one
described non-adherence because of an investigator-initiated
product interruption (hence reasons for non-adherence were
not participant related), and another participated only in the
week 8 interview (where no questions on adherence were
asked). This reduced our total sample size to 54 (29 were
randomized to FTC/TDF and 25 to placebo) and all discussed
pill use and misreporting. Among the 180 participants in the
HIV-negative group, 176 participants (FTC/TDF = 84,





Self-reported pill use in previous 7 days
Measure #1: C10 ng/mL plasma TFV among
visits where participants report C6 days
taking pills
38.0 420/1,105
Measure #2: C0.25 ng/mL plasma TFV
among visits where participants report
C1 days taking pills
42.2 490/1,162
Pill counts during each visit interval
Measure #3: C10 ng/mL plasma TFV and
C100,000 fmoles TFVdp/mL in ULPCs
among visits where pill-count data indicate
no more than 1 day without pill use
26.2 249/952
Self-reported pill use in previous 4 weeks
Measure #4: C10 ng/mL plasma TFV and
C100,000 femtomoles TFVdp/mL in ULPCs
among visits where participants report








Measure #1 Measure #2 Measure #3 Measure #4
Week of follow-up
Fig. 1 Positive predictive value
(the percent of visits where drug
concentration data were
consistent with the reported
adherence level) over time.
Refer to section on ‘‘Adherence
Measures and Analysis
Methods’’ for a detailed
description of each measure
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placebo = 92) discussed pill use, 63 (FTC/TDF = 31, pla-
cebo = 32) describedmisreporting, and 48 (FTC/TDF = 24,
placebo = 24) explained their comfort level in reporting
occurrences of non-adherence to study staffmembers.Among
the 57 exit interviews conducted, 56 participants (FTC/
TDF = 31, placebo = 25) described pill use and 54 (FTC/
TDF = 29, placebo = 25) described misreporting.
Study Product Non-use
Among the HIV-negative SSI group that was interviewed
during the clinical trial, many participants (56 %;
n = 99: FTD/TDF = 44, placebo = 55) said that they
had never missed taking their study pill. A common
response was:
I do not miss. I take it every day.—a 24-year-old
single woman from Pretoria who had 11 years of
education
However, some participants in all three SSIs groups said
that there were instances when they had not taken the study
pill. Some of these participants said that they had missed
their daily pill only once. Others reported that they had
missed pills over several consecutive days. Such accounts
of product non-use were more common among participants
in the exit SSI group (75 %; n = 42: FTC/TDF = 24,
placebo = 18) and the seroconverter SSI group (59 %;
n = 32: FTC/TDF = 17, placebo = 15) than among par-
ticipants in the HIV-negative SSI group (44 %; n = 77:
FTC/TDF = 40, placebo = 37). Regardless of the type of
group, descriptions of non-adherence suggested that par-
ticipants missed pills only occasionally, primarily because
of short-term travel or forgetfulness, and that this non-
adherence was not likely reflective of their overall
adherence:
Sometimes I would forget [to take the study pill] as I
left home thinking I would come back, [but] I didn’t.
That is when I would forget to drink them, but when I
was home I was able to drink them every day.
[Interviewer: So, how often would you say that hap-
pened?] It didn’t happen much, maybe two or three
times.—a 19-year-old single woman from Pretoria
who had 11 years of education and was in the HIV-
negative SSI group
Table 2 Odds ratios (OR) for
associations with misreporting
of adherence
Less than 10 ng/mL plasma
TFV when participants reported
taking pills at least 6 of the
previous 7 days
a Includes factors that remained
significant at the 0.05 level in
final adjusted model
b Bloemfontein, South Africa,
as reference
c Age 18–24 as reference
d Measured at nearest visit on
or before assessment of drug
concentration
e Some chance (small,
moderate, high) versus no
chance of getting HIV
Factor (‘‘yes’’ vs. ‘‘no’’ unless specified) Bivariate Multivariatea
OR (95 % CI) p value OR (95 % CI) p value
Baseline variables
Study siteb 0.164
Pretoria, South Africa 1.87 (0.96, 3.62)
Bondo, Kenya 1.86 (0.89, 3.90)
Agec 0.465
25-29 0.68 (0.35, 1.32)
C30 0.72 (0.31, 1.67)
C10 years of education 1.27 (0.66, 2.43) 0.478
Married 1.19 (0.61, 2.29) 0.610
Using OCs at enrollment 2.13 (1.12, 4.05) 0.021 2.26 (1.18, 4.35) 0.014
Using highly effective contraception at
screening
1.43 (0.79, 2.59) 0.241
Ever pregnant before enrollment 0.57 (0.30, 1.08) 0.084
Diagnosed with STI at baseline 1.24 (0.67, 2.29) 0.498
Variables assessed at study exit
Like daily pill-taking 0.55 (0.25, 1.18) 0.124
Randomization arm belief (placebo vs.
Truvada or don’t know)
1.48 (0.46, 4.77) 0.507
Time-dependent variablesd
Unprotected sex 1.24 (0.77, 1.98) 0.378
Have other sexual partners 1.07 (0.51, 2.24) 0.851
Gastrointestinal event 0.48 (0.15, 1.56) 0.225
HIV risk perceptione 0.62 (0.38, 1.01) 0.057
Time in study (weeks) 1.02 (1.01, 1.03) 0.002 1.02 (1.01, 1.03) \0.001
748 AIDS Behav (2015) 19:743–751
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Misreporting Product Non-use
Among the 54 participants who seroconverted, only two
(4 %, both FTC/TDF) said they had ever over-reported pill
use to study staff members; all others stated that they had
either given accurate reports or never missed taking a pill.
There are some two days that I forgot to take. I was
not around and I did not carry the pills. But I came
[to the study clinic] and reported.—a 20-year-old
married woman from Bondo who had 7 years of
education
Similarly, a minority of participants (19 %; n = 10: FTC/
TDF = 7, placebo = 3) in the exit interviews and very few
participants (5 %; n = 3: FTC/TDF = 1, placebo = 2) in
the HIV-negative group said they had inaccurately reported
missing pills to study staff members during the trial. Of
those who said they did not always report missing pills,
fears of being scolded or of being dropped from the study
were cited as key reasons.
Comfort with Reporting Non-adherence
Most of the 48 participants in theHIV-negative group (90 %;
n = 43: FTC/TDF = 20, placebo = 23) said they would be
comfortable reporting occurrences of non-adherence.
I am comfortable. I would just inform them so that
they will know—a 20-year-old single woman from
Bondo who had 10 years of education
Only five participants (10 %: FTC/TDF = 4, placebo = 1)
said they were uncomfortable telling staff that they did not
take their study pills as instructed.
Discussion
In the FEM-PrEP trial, misreporting of adherence was very
common—averaged over time, the positive predictive
values were less than 45 % for each of the four adherence
measures we assessed. Reports of taking at least one pill in
the previous 7 days appeared to have a somewhat higher
predictive value than the other measures. However, accu-
rate reports of this adherence level may not be especially
meaningful in terms of understanding the effectiveness of a
product intended to be used every day. More telling, self-
reports and pill counts that were intended to capture con-
sistent pill use over 4 week periods had the lowest pre-
dictive values (less than 30 % on average).
We had a large sample of drug concentrations for ana-
lysis (nearly 1,200 longitudinal visit records from 150
participants). However, our data on drug concentrations in
plasma TFV and intracellular TFVdp could be misleading
in certain circumstances. For example, different underlying
patterns of adherence can result in similar drug concen-
trations when the latter are assessed infrequently. In con-
trast, similar patterns of adherence can lead to different
drug concentrations due to heterogeneity of pharmacoki-
netic processes (e.g. absorption and metabolism) across
participants or populations. Likewise, unknown drug–drug
interactions could lead to bias when classifying adherence.
Recognizing these limitations, we chose conservative drug
concentration thresholds—ones that should be achieved
with a reasonable degree of certainty if a participant
adhered at the reported level—to assess the potential
accuracy of adherence reports. As a consequence, we may
have over-estimated the PPV, and under-estimated mis-
reporting, of the assessed adherence measures. We also
relied on plasma concentrations when assessing reports of
high adherence in the previous 7 days (Measure #1). Due
to the short half-life of TFV in plasma, a participant who
only took a pill shortly before going to the clinic (‘‘white
coat adherence’’) could achieve plasma concentrations
similar to those of participants who truly adhered at a high
level. We would have misclassified such women as cor-
rectly reporting high adherence, and under-estimated the
rate of misreporting. Finally, we recognize that the data
obtained from the SSIs did not focus on a specific time
point, so we cannot triangulate the qualitative and quanti-
tative results on adherence.
In the primary multivariate analysis, the choice of OCs
for pregnancy prevention at enrollment was significantly
associated with misreporting. Given that women choosing
to use OCs also had very high pregnancy rates [15], this
result suggests that participants may have concealed
instances of non-adherence to both contraceptive use and
study pill use. Time in the study also remained significant
in the primary multivariate analysis, with the level of
misreporting generally increasing over time. This may
reflect a trend towards lower adherence over time rather
than an indication that the participants increased the rate at
which they reported adhering.
Given the magnitude of over-reporting in quantitative
self-reported measures, we believe that participants also
over-reported adherence through the qualitative interviews.
One of the strengths of qualitative methods is the ability to
explore personal or sensitive information [16, 17]. How-
ever, the participants’ fears of perceived repercussions of
non-adherence (such as being discontinued from the trial)
may not necessarily be alleviated based on the type of
method (quantitative or qualitative) used to solicit experi-
ences with adherence when the information is ultimately
reported by participants to study staff members at the study
clinic. Although there were slight differences in the par-
AIDS Behav (2015) 19:743–751 749
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ticipants’ qualitative descriptions of non-adherence, of
their misreporting of adherence, and of their comfort level
in reporting occurrences of non-adherence between the two
study arms, the overall number of participants is too small
to make any valid conclusions about these differences. Our
findings from the exit interviews also suggest that partici-
pants may have been more comfortable sharing accounts of
product non-use after the trial announced it was closing
early. Based on a similar premise, we conducted follow-up
interviews with FEM-PrEP participants to identify the
reasons for non-adherence and misreporting many months
after all FEM-PrEP clinical and community activities were
completed. The findings will be presented elsewhere.
With such high levels of misreporting, we must not only
continue to improve methods to reduce socially desirable
responses through participant self-report, but also closely
examine the reasons why participants join HIV-prevention
clinical trials in the first place. Improvements to adherence
counselling and participant self-reports will only be bene-
ficial if study populations enroll in such trials with some
interest in taking the study product. Given that many FEM-
PrEP participants said that they adhered to pill taking as
instructed, it is difficult to fully understand why they did
not in fact take the study product yet consistently came for
clinic visits and underwent the study procedures, or why
they concealed their non-adherence. Clearly, participants
perceived some benefit of remaining in the clinical trial
while not taking the study product. Other FEM-PrEP data
have suggested that several participants took part in the
FEM-PrEP trial for the personal benefits they would
receive, such as care and treatment for common illnesses
and ongoing HIV testing [18]. Further research is needed in
this area.
The large discrepancy we found between adherence
assessed through self-report or pill-count and adherence
assessed through drug concentrations or other biomarkers
is not unique to FEM-PrEP. In the Carraguard trial [19],
self-reported adherence was 94 %, yet on the basis of
applicator testing, the study gel was estimated to have been
used in only 42.1 % of sex acts. In the HSV-2 suppression
therapy trial [20], acyclovir was detected in 55 % of par-
ticipants’ urine, yet adherence by pill count was 90 %.
Adherence measured by pill count and self-report in the
iPrEx trial [21] was 93 %, yet a sub-study of drug con-
centrations showed that only 50 % of participants were
actually swallowing their pills and only 9 % of those who
seroconverted (n = 36) had any drug in their cells. Fur-
thermore, in the VOICE trial [6], adherence to the pills or
microbicide was 93 %, according to product counts and
self-reports; however, only 28–29 % of participants
assigned to TDF or FTC/TDF, and 22 % of participants
assigned to the TFV 1 % gel, had detectable drug levels in
blood (or vaginal fluids in the case of the microbicide).
Conclusions
In summary, participant-dependent measures of adherence
were unreliable in FEM-PrEP. Although expensive and
logistically challenging, pharmacokineticmonitoring remains
the measure of choice until more reliable participant-depen-
dent measures are developed.Methods are currently available
tomeasure drug concentrations in participants’ blood, cells, or
other biological matrices, such as cervicovaginal fluids, in
trials with topical products. In future clinical trials, data on
drug concentrations could be utilized in addition to more
reliable participant-dependent measures and pharmacy refills
to inform overall adherence on a real-time basis. Such results,
however, should not be used to counsel individual participants
as that may un-blind the study; rather, the results should be
used to offer generalized counselling to all participants about
the overall level of adherence in the study. In addition, future
research should explore whether in-depth interviews con-
ducted by non-clinic-based staff members and at locations
outside the study clinic allow participants who are experi-
encingproblemswith adherence to bemorewilling to disclose
their difficulties or concerns.
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